Oncology
HR+ HER2- Early Breast Cancer
Conference Reporter® Podcast: Genomic Assays in HR+/HER2- Early-Stage Breast Cancer
Genomic assays have helped clinicians estimate distant recurrence risk and guide treatment decisions in HR+/HER2- early-stage breast cancer. In this podcast interview, Joseph A. Sparano, MD, FACP, FASCO, discusses how findings from the 2026 ASCO Annual Meeting, including data from the OPTIMA and NATALEE trials, may inform current practice and future research.
Following these presentations, featured expert Joseph A. Sparano, MD, FACP, FASCO, was interviewed by Conference Reporter Associate Editor-in-Chief Christopher Ontiveros, PhD. Clinical perspectives from Dr Sparano on these findings are presented here.
Brufsky AM. Predictive and prognostic value of the 21-gene recurrence score in hormone receptor-positive, node-positive breast cancer. Am J Clin Oncol. 2014;37(4):404-410. doi:10.1097/COC.0000000000000086
Chia SK, Fasching PA, Crown J, et al. Prognostic and predictive impact of baseline gene expression (exp) in the NATALEE trial of adjuvant (adj) ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in HR+/HER2- early breast cancer (EBC) [abstract 501] [session: Breast cancer—local/regional/adjuvant]. Abstract presented at: 2026 American Society of Clinical Oncology Annual Meeting; May 29-June 2, 2026; Chicago, IL.
Hyams DM, Bareket-Samish A, Rocha JEB, et al. Selecting postoperative adjuvant systemic therapy for early-stage breast cancer: an updated assessment and systematic review of leading commercially available gene expression assays. J Surg Oncol. 2024;130(2):166-187. doi:10.1002/jso.27692
Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24(23):3726-3734. doi:10.1200/JCO.2005.04.7985
Piccart MJ, Kalinsky K, Gray R, et al. Gene expression signatures for tailoring adjuvant chemotherapy of luminal breast cancer: stronger evidence, greater trust. Ann Oncol. 2021;32(9):1077-1082. Published correction appears in Ann Oncol. 2022;33(6):668.
Sparano JA, Crager MR, Tang G, Gray RJ, Stemmer SM, Shak S. Development and validation of a tool integrating the 21-gene recurrence score and clinical-pathological features to individualize prognosis and prediction of chemotherapy benefit in early breast cancer. J Clin Oncol. 2021;39(6):557-564. doi:10.1200/JCO.20.03007
Stein RC, Makris A, Macpherson IR, et al; OPTIMA Investigators and Trial Management Group. First results from the OPTIMA phase III randomized non-inferiority trial of test-directed chemotherapy in patients with high clinical risk ER-positive HER2-negative early breast cancer [abstract 500] [session: Breast cancer—local/regional/adjuvant]. Abstract presented at: 2026 American Society of Clinical Oncology Annual Meeting; May 29-June 2, 2026; Chicago, IL.
Zeng C, Zhang J. A narrative review of five multigenetic assays in breast cancer. Transl Cancer Res. 2022;11(4):897-907. doi:10.21037/tcr-21-1920
This information is brought to you by Engage Health Media and is not sponsored, endorsed, or accredited by the American Society of Clinical Oncology.
Explore More in HR+ HER2- Early Breast Cancer
HR+ HER2- Early Breast Cancer
Managing Endocrine Therapy–Related Side Effects and Adherence in HR+/HER2- Early-Stage Breast Cancer
HR+ HER2- Early Breast Cancer
Expert Roundtables Podcast: Neoadjuvant Therapy for HR+/HER2- Early-Stage Breast Cancer
HR+ HER2- Early Breast Cancer
From Fatigue to Function: Unpacking Multidriver Symptom Clusters in Early-Stage Breast Cancer
HR+ HER2- Early Breast Cancer